Skip to main content
. 2023 Apr 3;11(4):1082. doi: 10.3390/biomedicines11041082

Figure 1.

Figure 1

Overview of the study. Tumor tissue and whole blood were collected from pediatric patients diagnosed with cancer. Tumor tissue DNA was extracted and underwent either bisulfite conversion followed by hybridization in the EPIC BeadChip Methylation Arrays or SALSA MLPA assay. CNAs were obtained from either EPIC or MLPA data. Tumors with 1q gain, MYCN gain or TP53 gain/loss were selected for dPCR. Plasma was used for cfDNA extraction and for CNAs’ evaluation. WT, Wilms tumor; NB, neuroblastoma; ES, Ewing sarcoma; RMS, rhabdomyosarcoma; LMS, leiomyosarcoma; OS, osteosarcoma; and BT, benign teratoma.